All In Biotech

Drug Trial Radar · NCT04460651

PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial

Last checked: Nov 20, 2026Latest source record: Sep 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 4,093 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,093

Actual

Start

Aug 14, 2020

Primary completion

Aug 30, 2021

Study completion Aug 30, 2021

Sponsor

Lead sponsor
Estudios Clínicos Latino AméricaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Amarin Pharma Inc.
First posted
Jul 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The PREPARE-IT investigator-initiated trial program is a simple, pragmatic, therapeutic strategy evaluating pure icosapent ethyl (IPE) at initially higher doses intended to reduce infection rates and subsequent morbidity and mortality among subjects at high risk of infection due to COVID-19 (prevention arm), and to reduce the hospitalization rate and complications in patients with a positive diagnosis of COVID-19 (treatment arm).

Conditions

  • COVID19

Interventions

  • Icosapent ethyl (IPE)Drug

    Participants in this arm will receive study medication IPE with the following dosage schedule: 8 g of IPE (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of IPE (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)

  • PlaceboDrug

    Participants in this arm will receive placebo with the following dosage schedule: 8 g of placebo (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of placebo (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. (A) Prevention Arm: SARS-CoV-2 positivity assesed up to day 60.Time frame: 60 days
  2. (B) Treatment Arm: COVID 19 related hospitalization (indication for hospitalization per the blinded investigator or actual hospitalization) or death assessed up to 28 daysTime frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Instituto de Investigaciones Clínicas - Rosario

    Rosario, Santa Fe Province, Argentina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.